You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

lung cancer RET inhibitor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Shanghai (SY-5007)

Recruiting
  • Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Sep 4, 2023

NSCLC, Thyroid Tumors Trial (LOXO-260)

Temporarily not available
  • Carcinoma, Non-Small-Cell Lung
  • Thyroid Neoplasms
  • (no location specified)
Sep 20, 2022

Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Tampa

Recruiting
  • Lung Non-Small Cell Carcinoma
  • +4 more
  • Tampa, Florida
    Moffitt Cancer Center
Aug 16, 2022

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

Advanced Solid Tumor Trial (HEC169096)

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
Jul 6, 2022

Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation Trial in Korea, Republic of, United States (TPX-0046)

Recruiting
  • Non Small Cell Lung Cancer
  • +4 more
  • Irvine, California
  • +15 more
Mar 9, 2022

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

Active, not recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +39 more
  • pralsetinib (BLU-667)
  • Phoenix, Arizona
  • +65 more
Nov 10, 2022

Nonsmall Cell Lung Cancer Trial in Shanghai (HS-10365 capsules)

Recruiting
  • Nonsmall Cell Lung Cancer
  • HS-10365 capsules
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Nov 22, 2023

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Chang chun

Not yet recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +3 more
  • Chang chun, Jilin, China
    Jinlin Province Cancer Hosipital
Dec 21, 2022

NSCLC, NSCLC Metastatic, NSCLC Recurrent Trial in Worldwide (Alectinib)

Terminated
  • Non-small Cell Lung Cancer
  • +2 more
  • Brussels, Belgium
  • +18 more
Aug 23, 2022

Malignant Thyroid Gland Tumor, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma Trial in Houston

Recruiting
  • Malignant Thyroid Gland Neoplasm
  • +6 more
  • Quality-of-Life Assessment
  • +3 more
  • Ann Arbor, Michigan
  • +1 more
Jan 24, 2023

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion

Recruiting
  • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 1, 2022

    NSCLC Trial in Guangzhou (HA121-28 tablet)

    Recruiting
    • NSCLC
    • HA121-28 tablet
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Centre
    Aug 2, 2022

    ALK-positive NSCLC (NSCLC), RET-positive NSCLC (NSCLC), RET-positive Thyroid Cancer Trial in Irvine, Boston (Alectinib)

    Terminated
    Has Results
    • ALK-positive Non-small Cell Lung Cancer (NSCLC)
    • +2 more
    • Irvine, California
    • +3 more
    Aug 30, 2021

    NSCLC, Medullary Thyroid Cancer, Solid Tumor Trial in Shanghai, Tianjin (SY-5007)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +2 more
    • Shanghai, Shanghai, China
    • +1 more
    Mar 17, 2022

    NSCLC (NSCLC) Trial (Alirocumab and Cemiplimab)

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • Alirocumab and Cemiplimab
    • (no location specified)
    Jan 31, 2023

    Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

    Recruiting
    • Advanced Solid Tumor
    • Refractory Tumor
    • Radiotherapy
    • +4 more
    • Suzhou, China
      The Second Affiliated Hospital of SchoowUniversity
    Sep 14, 2023

    NSCLC Trial in Omaha (PLB1004)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • Omaha, Nebraska
      Nebraska Cancer Specialists
    Sep 19, 2023

    Lung Cancer Trial (TILT-123, Pembrolizumab)

    Not yet recruiting
    • Lung Cancer
    • TILT-123
    • Pembrolizumab
    • (no location specified)
    Nov 5, 2023

    NSCLC, Medullary Thyroid Cancer, Colon Cancer Trial in Worldwide (LOXO-292)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +3 more
    • Scottsdale, Arizona
    • +84 more
    Oct 10, 2022

    Advanced Lung Squamous Cell Carcinoma Trial in Chengdu (low-dose radiation therapy and stereotactic body radiation therapy,

    Not yet recruiting
    • Advanced Lung Squamous Cell Carcinoma
    • low-dose radiation therapy and stereotactic body radiation therapy
    • +2 more
    • Chengdu, Sichuan, China
      West China Hospital of Sichuan University
    Nov 13, 2023

    Advanced Malignant Tumor, Metastatic Malignant Tumor, Recurrent Malignant Tumor Trial in Houston (Everolimus, Laboratory

    Recruiting
    • Advanced Malignant Neoplasm
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 9, 2022

    LMV-12 Combined With Osimertinib in NSCLC

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • LMV-12(HE003) and Osimertinib
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Oct 25, 2023

    Non Small Cell Lung Cancer Trial in Montréal (increasing total fiber intake)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • increasing total fiber intake
    • Montréal, Quebec, Canada
      Centre hospitalier de l'Université de Montréal (CHUM)
    Apr 6, 2023

    Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

    Not yet recruiting
    • Lung Cancer
    • Centipeda minima+PD-1/PD-L1 inhibitor
    • PD-1/PD-L1 inhibitor
    • (no location specified)
    Feb 17, 2023